pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-28 |
Genomic Coordinates | chr3: 188688781 - 188688866 |
Synonyms | MIRN28, hsa-mir-28, miR-28, MIR28 |
Description | Homo sapiens miR-28 stem-loop |
Comment | None |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | ||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-28-5p | |||||||||||||||||||||||||||
Sequence | 14| AAGGAGCUCACAGUCUAUUGAG |35 | |||||||||||||||||||||||||||
Evidence | Experimental | |||||||||||||||||||||||||||
Experiments | Cloned | |||||||||||||||||||||||||||
Editing Events in miRNAs |
|
DRVs in miRNA |
|
|||||||||||||||||||||||||
SNPs in miRNA |
|
|||||||||||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | E2F6 | ||||||||||||||||||||
Synonyms | E2F-6 | ||||||||||||||||||||
Description | E2F transcription factor 6 | ||||||||||||||||||||
Transcript | NM_198256 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on E2F6 | |||||||||||||||||||||
3'UTR of E2F6 (miRNA target sites are highlighted) |
>E2F6|NM_198256|3'UTR 1 TGGCATTTGAGAATTTATGTATCACTGAGTTTTTTGGGAATATCTTCGTGGAGAATTACGCATCAAATTTGATTCTCAGA 81 GCAATAAATTATCCATGAAGTGCTCTCGTTCTCAGTAGCGGCATCATGGCCAGTAGTGTCTTTGAGGAGTTCACCACTTA 161 GATTACTGAGTAATTGTGGTTTCCACATTTGAAAACAACTCCTTTTATAATTATTCACTGCTTTTTGTCAGTGAAATAGA 241 CATCTTGCCTCCTGAAGTAGCTTCATCACAGAGTGTCATGAAGACAGACAGTCAGGCTGAAATGGACAGTTCTTTGTGGA 321 CTCTACCCTTCCCTTCAAGGAGTATGTCATATATCACAAAAGAAATTGCCTTACACTGGTTCATGTTTGCAGTTACTGTT 401 GTACATTGCATAGATGTACACACGAATTTAAATGTGATGTCTTTGTATATATCTGTATAATGTTGAGATTACTTACGAAA 481 TATGTCTGAGTGACACTTTTCACCCTTGTACAGCCAAAATAATGTATATATGGAAAGTGACAGACAAATTCTCTAATCTC 561 TTTGGTACCTATAACTTATTAGAATCCTCTGGATGAGGGTTAGAAGAGACTTTTTCCAAACTTCTACATGTAGAAGTATC 641 ATAAATGTGCTACACATTTATGTTTGTGGATTTAATTAAAGTATTTTAATATGGTTTTCAGTGCTAAAATTGGAGTCAGA 721 TACTTCTTGGTTTTAAGCTGTCTACCTAATTGCTGTCTCCCAGCAGACTGGTGGCATGCCCAGTGGCTTTGGGGGCAAGG 801 ATAGAAATGCCATCAGGAAATAGCTGAATTCATTGTGAAACATGAATTCAGTCATGGTGATAATTGGAAACTCCTTTCAG 881 GTTTTTGCAAGTAGATTTTGTAATGTTTGTGTATGCAGCCTTGCTGTTGAGTCAGTCCAAGGGGTTTTACTTAGGACAAG 961 TTGTACCTTGCCCTCTCTCCAGCTCTGCTCCCACATTTTCACATACCTAGCTGTTTCTACCTCATTGGGTAAGTCATTTA 1041 CCACTCTGTGCCTCAGTTTACTCTGTAGTTTACCATTAGACTGTGAGCTCCTTGAGGGACTTTGTCATAATCACTGTTAC 1121 ATCCCAGTGCCTCACACCATGCCTGGCCCTTAAGAAGTGCTCAATAAATGTCTGAACAAATAAGTGAGTGGAGTGAGTGA 1201 ATTGTAAGATCAGAATAATAATATTTGGTTTGTCTATCGTACAAGATTCCTGTATCGTTTGAATATTGCTTTTAAAGAAA 1281 TATTTGAAGCGACTTCAAATTCAGACTGTGTTTAAAAAGATTTAAAATCGGAATCCAAAATCAAAGTATTAAAAAATAAT 1361 GCTGAGTGTTTAGGATTCACATACCTCTGAGCTCTGGTGGCTTTTGCCAGTCCTGTCCCTCTGCTGAGCACCAGCCCTTC 1441 CTGCAGCAGTCCTGCCGGTGTGTTTCTGTGCACCTGGGGATGAAGTGTGCTCCTCCCCCAGCGGTTAGCCTCAATGCTTT 1521 TCCTCCCTCTGTTTTATTATTTGAAATTAGCCAAAGAAAAGCTGCAGGGGGCACTGCTGATCATCACTGGACTGGTGGGT 1601 CGTACTGTTTGACAGAATAGGGAATACAGGAGGAGGAGCAAGCCTAGGGTAAAACTTAGGTTTGGGACATGCTTGATGAA 1681 AGCAAGAGTTGAGCAGGTTGTTGTGTGTATGTAGGTCAGGTGCTCAGCGGAAAAGTCTGAGCTGTGTAGTACGTCAGGCA 1761 GATGTCAGTTTAGATGCGATAGTTTAAGCCACAAGAGTAGGAGAGGTCATCTAAAGAGTACAGCAGGCCTAAGGGCATCT 1841 ATATTTAAGGAGAAATACAGAAGAAGTCTCCTGAGAAGGAATAATGGGGCGGGTGGGGAGGGAGAAGGCAGTGTCCCAAA 1921 AACCAACAAAGGTTTTACCAAAGGTAATACCATCATTTCTGAGCAGCAGTTCCTTAACTTGTGAATGTGGCAAATGTTCT 2001 CCTTTACAAATTGTTCTGAAGGTAAAATGAGATCATGTAAACGAAAATCCTTTGTAAATTACAGATGTGTGTTATAAATG 2081 AAGTATCTCTCGAGTCACTCCA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | Mo7e |
Location of target site | 3'UTR |
Original Description (Extracted from the article) |
...
"miR-28 and closely related miR-151 and miR-708 inhibit Tpodependent proliferation of Mo7e cells and target mRNAs coding for proteins involved in proliferation and apoptosis.//E2F6 (E2F transcription factor 6) was inhibited by miR-28 and -151 by 40% and 20%
... - Girardot M; Pecquet C; Boukour S; Knoops L; et al., 2010, Blood. |
Article |
- Girardot M; Pecquet C; Boukour S; Knoops L; et al. - Blood, 2010
BCR-ABL negative myeloproliferative neoplasms (MPNs; polycythemia vera, essential thrombocythemia, primary myelofibrosis) are malignant diseases arising from a multipotent hematopoietic progenitor, frequently altered by JAK2 V617F or other JAK/STAT activating mutations. The thrombopoietin receptor (TpoR, MPL) is one of the major dimeric cytokine receptors that use JAK2 in the myeloid lineage, and was found to be down-modulated in certain MPN patients. We searched for negative regulators of MPL expression. Here we report that miR-28 targets the 3' untranslated (3'UTR) region of MPL, inhibiting its translation, as well as other proteins potentially involved in megakaryocyte differentiation, such as E2F6. Expression of miR-28 in CD34-derived megakaryocytes inhibited terminal differentiation. miR-28 was found to be overexpressed in platelets of a fraction of MPN patients, while it was expressed at constant low levels in platelets from healthy subjects. Constitutive activation of STAT5 leading to autonomous growth of hematopoietic cell lines was associated with increased miR-28 expression. We discuss how down-modulating MPL and other targets of miR-28, and of related miR-708 and miR-151, could contribute to MPN pathogenicity.
LinkOut: [PMID: 20445018]
|
CLIP-seq Support 1 for dataset GSM4903825 | |
---|---|
Method / RBP | HITS-CLIP / AGO |
Cell line / Condition | Dermal fibroblasts / PID14_NS |
Location of target site | NM_198256 | 3UTR | AGACUGUGAGCUCCUUGAGGGAC |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Accession Series | GSE161237 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
82 hsa-miR-28-5p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT000595 | CDKN1A | cyclin dependent kinase inhibitor 1A | 4 | 1 | ||||||||
MIRT006402 | MPL | MPL proto-oncogene, thrombopoietin receptor | 3 | 1 | ||||||||
MIRT006411 | N4BP1 | NEDD4 binding protein 1 | 1 | 1 | ||||||||
MIRT006414 | OTUB1 | OTU deubiquitinase, ubiquitin aldehyde binding 1 | 1 | 1 | ||||||||
MIRT006416 | TEX261 | testis expressed 261 | 1 | 1 | ||||||||
MIRT006418 | MAPK1 | mitogen-activated protein kinase 1 | 1 | 1 | ||||||||
MIRT006419 | E2F6 | E2F transcription factor 6 | 1 | 1 | ||||||||
MIRT049989 | ZCCHC3 | zinc finger CCHC-type containing 3 | 1 | 1 | ||||||||
MIRT049990 | TPM4 | tropomyosin 4 | 1 | 1 | ||||||||
MIRT049991 | TULP4 | tubby like protein 4 | 1 | 1 | ||||||||
MIRT049992 | SNX1 | sorting nexin 1 | 1 | 1 | ||||||||
MIRT049993 | IMPDH1 | inosine monophosphate dehydrogenase 1 | 1 | 1 | ||||||||
MIRT049994 | AAAS | aladin WD repeat nucleoporin | 1 | 1 | ||||||||
MIRT049995 | CENPV | centromere protein V | 1 | 1 | ||||||||
MIRT049996 | NRN1 | neuritin 1 | 1 | 1 | ||||||||
MIRT049997 | GEMIN4 | gem nuclear organelle associated protein 4 | 1 | 1 | ||||||||
MIRT049998 | ZBTB47 | zinc finger and BTB domain containing 47 | 1 | 1 | ||||||||
MIRT049999 | UNG | uracil DNA glycosylase | 1 | 1 | ||||||||
MIRT050000 | CNN3 | calponin 3 | 1 | 1 | ||||||||
MIRT050001 | KLHL12 | kelch like family member 12 | 1 | 1 | ||||||||
MIRT050002 | TLK1 | tousled like kinase 1 | 1 | 1 | ||||||||
MIRT050003 | SREBF2 | sterol regulatory element binding transcription factor 2 | 4 | 1 | ||||||||
MIRT050004 | RAB36 | RAB36, member RAS oncogene family | 1 | 1 | ||||||||
MIRT050005 | ZNF106 | zinc finger protein 106 | 1 | 1 | ||||||||
MIRT050006 | SETD7 | SET domain containing lysine methyltransferase 7 | 1 | 1 | ||||||||
MIRT050007 | DENND4B | DENN domain containing 4B | 1 | 1 | ||||||||
MIRT050008 | CS | citrate synthase | 1 | 1 | ||||||||
MIRT050009 | CD276 | CD276 molecule | 1 | 1 | ||||||||
MIRT050010 | TUFM | Tu translation elongation factor, mitochondrial | 1 | 1 | ||||||||
MIRT050011 | SMYD1 | SET and MYND domain containing 1 | 2 | 5 | ||||||||
MIRT050012 | SIK1 | salt inducible kinase 1 | 1 | 1 | ||||||||
MIRT054748 | MAD2L1 | mitotic arrest deficient 2 like 1 | 3 | 1 | ||||||||
MIRT054749 | BAG1 | BCL2 associated athanogene 1 | 3 | 1 | ||||||||
MIRT054750 | RAP1B | RAP1B, member of RAS oncogene family | 3 | 1 | ||||||||
MIRT317835 | CCND3 | cyclin D3 | 2 | 2 | ||||||||
MIRT367642 | ARHGAP42 | Rho GTPase activating protein 42 | 2 | 4 | ||||||||
MIRT443876 | DDTL | D-dopachrome tautomerase like | 2 | 2 | ||||||||
MIRT447544 | RNF165 | ring finger protein 165 | 2 | 2 | ||||||||
MIRT447611 | PCYOX1 | prenylcysteine oxidase 1 | 2 | 2 | ||||||||
MIRT447838 | CTIF | cap binding complex dependent translation initiation factor | 2 | 2 | ||||||||
MIRT448193 | FAM168A | family with sequence similarity 168 member A | 2 | 2 | ||||||||
MIRT448713 | KLHL11 | kelch like family member 11 | 2 | 2 | ||||||||
MIRT450179 | KLF7 | Kruppel like factor 7 | 2 | 2 | ||||||||
MIRT450312 | DRAXIN | dorsal inhibitory axon guidance protein | 2 | 2 | ||||||||
MIRT460792 | VPS37B | VPS37B, ESCRT-I subunit | 2 | 2 | ||||||||
MIRT466332 | THRA | thyroid hormone receptor, alpha | 2 | 2 | ||||||||
MIRT467610 | SLC7A5 | solute carrier family 7 member 5 | 2 | 2 | ||||||||
MIRT471609 | PAQR5 | progestin and adipoQ receptor family member 5 | 2 | 2 | ||||||||
MIRT472144 | NKIRAS2 | NFKB inhibitor interacting Ras like 2 | 2 | 4 | ||||||||
MIRT476588 | G3BP1 | G3BP stress granule assembly factor 1 | 2 | 4 | ||||||||
MIRT486265 | LINC00346 | long intergenic non-protein coding RNA 346 | 2 | 4 | ||||||||
MIRT486480 | TSC22D1 | TSC22 domain family member 1 | 2 | 2 | ||||||||
MIRT487978 | IQSEC2 | IQ motif and Sec7 domain 2 | 2 | 2 | ||||||||
MIRT489428 | TUBB2A | tubulin beta 2A class IIa | 2 | 2 | ||||||||
MIRT500781 | TMED4 | transmembrane p24 trafficking protein 4 | 2 | 6 | ||||||||
MIRT501235 | SEMA4C | semaphorin 4C | 2 | 6 | ||||||||
MIRT511045 | NRF1 | nuclear respiratory factor 1 | 2 | 2 | ||||||||
MIRT512837 | IER3 | immediate early response 3 | 2 | 2 | ||||||||
MIRT513091 | USP9X | ubiquitin specific peptidase 9, X-linked | 2 | 2 | ||||||||
MIRT513543 | PRDM2 | PR/SET domain 2 | 2 | 4 | ||||||||
MIRT532391 | UMPS | uridine monophosphate synthetase | 2 | 2 | ||||||||
MIRT535846 | MSI2 | musashi RNA binding protein 2 | 2 | 2 | ||||||||
MIRT537892 | EDA2R | ectodysplasin A2 receptor | 2 | 2 | ||||||||
MIRT552769 | YIPF6 | Yip1 domain family member 6 | 2 | 2 | ||||||||
MIRT553549 | TMEM167A | transmembrane protein 167A | 2 | 4 | ||||||||
MIRT557228 | HNRNPC | heterogeneous nuclear ribonucleoprotein C (C1/C2) | 2 | 2 | ||||||||
MIRT566756 | MORF4L1 | mortality factor 4 like 1 | 2 | 2 | ||||||||
MIRT567505 | FOXJ3 | forkhead box J3 | 2 | 2 | ||||||||
MIRT568165 | CCDC6 | coiled-coil domain containing 6 | 2 | 2 | ||||||||
MIRT570263 | PRSS16 | protease, serine 16 | 2 | 2 | ||||||||
MIRT614727 | TEAD3 | TEA domain transcription factor 3 | 2 | 2 | ||||||||
MIRT668894 | CRISPLD2 | cysteine rich secretory protein LCCL domain containing 2 | 2 | 2 | ||||||||
MIRT691021 | CRTC3 | CREB regulated transcription coactivator 3 | 2 | 2 | ||||||||
MIRT697421 | ZFP91 | ZFP91 zinc finger protein | 2 | 2 | ||||||||
MIRT711474 | SRD5A1 | steroid 5 alpha-reductase 1 | 2 | 2 | ||||||||
MIRT720189 | CMC4 | C-X9-C motif containing 4 | 2 | 2 | ||||||||
MIRT720622 | PIANP | PILR alpha associated neural protein | 2 | 2 | ||||||||
MIRT731420 | IGF1 | insulin like growth factor 1 | 3 | 1 | ||||||||
MIRT732850 | LINC00265 | long intergenic non-protein coding RNA 265 | 3 | 0 | ||||||||
MIRT732851 | PCNA | proliferating cell nuclear antigen | 3 | 0 | ||||||||
MIRT736342 | FOXO1 | forkhead box O1 | 3 | 0 | ||||||||
MIRT755341 | YWHAZ | tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta | 3 | 1 |
miRNA-Drug Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|